Breast Cancer Stamp Debuts in June

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

WASHINGTON--The US Postal Service will release its Breast Cancer Awareness stamp on June 15, in conjunction with the 1996 National Race for the Cure, the 5K race that raises money to fund breast cancer research, education, treatment, and screening.

WASHINGTON--The US Postal Service will release its Breast CancerAwareness stamp on June 15, in conjunction with the 1996 NationalRace for the Cure, the 5K race that raises money to fund breastcancer research, education, treatment, and screening.

Race for the Cure was founded by the Susan G. Komen Breast CancerFoundation, established in 1982 by Nancy Brinker in memory ofher sister Susan G. Komen, who died of breast cancer at the ageof 36.

Sale of the stamp will launch a 4-month public service campaignduring which the Postal Service will join with the YWCA's ENCOREplusprogram, the American Cancer Society, Lifetime Television, andseveral breast cancer groups in providing information and mammographyscreenings at neighborhood post offices and other community locations.

The NCI's Cancer Information Service toll-free number (1-800-4-CANCER)will be printed on the top border of each sheet of 20 stamps.One hundred million stamps will be printed.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Related Content